Log in to search using one of your social media accounts:

 

Kazia Receives FDA Orphan Designation for GDC-0084
SYDNEY, Feb. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) ... Biopharmaceuticals, Oncology, FDA Kazia Therapeutics, GDC-0084, glioblastoma multiforme (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2018 Category: Pharmaceuticals Source Type: news

VoCare Develops the World's First Mobile Professional Grade Medical Multi-Diagnostic Device, Which Provides a Revolutionary Integrated Mobile Point-of-Care Solution as Well as a Remote Patient Monitoring Solution
INDIANAPOLIS, Feb. 23, 2018 -- (Healthcare Sales & Marketing Network) -- VoCare, Inc., an Indiana-based company, has developed the world's first professional grade medical diagnostic device which collects 6 different health vitals and is equipped with WiF... Devices, Monitoring VoCare, Vitals360 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2018 Category: Pharmaceuticals Source Type: news

Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Application Based on Data From Largest International Multiple Myeloma Trial for the Prevention of Skeletal-Related Events Ever Conducted THOUSAND OAKS, Calif., Feb. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announ... Biopharmaceuticals, Oncology, Regulatory Amgen, XGEVA, denosumab, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2018 Category: Pharmaceuticals Source Type: news

Getinge announces U.S. Food and Drug Administration 510(k) clearance for PulsioFlex Monitoring System and PiCCO Module
Getinge plans to launch advanced patient monitoring system and accompanying hemodynamic monitoring technology in the United States during the first quarter of 2018 for use with critically ill patients WAYNE, N.J, Feb. 23, 2018 -- (Healthcare Sales & Mar... Devices, Monitoring, FDA Getinge, Maquet, PulsioFlex, PiCCO Module (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2018 Category: Pharmaceuticals Source Type: news

Vascular Graft Solutions: External Stenting of Vein Grafts is Associated With High Early Patency Rates
Interim report from the post-marketing randomized VEST III trial TEL AVIV, Israel, Feb. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Vascular Grafts Solutions announced today the interim results from the VEST III study, a post-marketing trial ... Devices, Cardiology Vascular Grafts Solutions, Venous External SupporT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2018 Category: Pharmaceuticals Source Type: news

Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
Action date set for August 22, 2018 STAINES-UPON-THAMES, United Kingdom, Feb. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug ... Biopharmaceuticals, FDA Mallinckrodt, stannsoporfin, hyperbilirubinemia, jaundice (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2018 Category: Pharmaceuticals Source Type: news

GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer
Decipher testing recognized as standard-of-care in management of prostate cancer patients SAN DIEGO, Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced tha... Diagnostics, Oncology GenomeDx Biosciences, NCCN, Decipher Prostate, Prostate Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

NN, Inc. Announces The Acquisition Of Bridgemedica, LLC
JOHNSON CITY, Tenn., Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- NN, Inc., (NASDAQ: NNBR) a diversified industrial company, today announced it has completed the acquisition of the assets of Bridgemedica, LLC ("Bridgemedica"), a me... Devices, Mergers & Acquisitions NN , Bridgemedica (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Access Vascular Receives FDA Clearance For Its HydroPICC Catheter
The HydroPICC Uses Proprietary Technology Designed to Reduce Thrombosis BEDFORD, Mass., Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Access Vascular, a medical device company reinventing venous access using proprietary material technology... Devices, FDA Access Vascular, HydroPICC, peripherally inserted central catheter (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Varian Acquires Evinance Innovation, Inc.
Expands 360 Oncology care management platform with clinical decision support PALO ALTO, Calif., Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Varian (NYSE: VAR) today announced it has acquired privately-held Montreal-based Evinance Innovat... Devices, Oncology, Mergers & Acquisitions Varian Medical Systems, Evinance Innovation, 360 Oncology, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Hoth Therapeutics Inc. Announces Completion of Series A Financing
NEW YORK, Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from in... Biopharmaceuticals, Dermatology, Venture Capital Hoth Therapeutics, atopic dermatitis, eczema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology SANTA MONICA, Calif. and RICHMOND, Calif., Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Kite, a... Biopharmaceuticals, Oncology, Licensing Sangamo Therapeutics, Kite, Gilead, zinc finger nuclease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Kallyope Inc. Announces $66M Series B Financing to Advance Programs Targeting the Gut-Brain Axis
All existing backers including Lux Capital, The Column Group, and Polaris Partners joined by new investors Euclidean Capital and Two Sigma Ventures Progress in building a comprehensive map of gut-brain circuits and identification of therapeutic opportun... Biopharmaceuticals, Neurology, Venture Capital Kallyope, gut-brain axis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Medtronic Introduces MiniMed(TM) Mio(TM) Advance Infusion Set for People with Diabetes
New Infusion Set Offers Simpler, Faster, and More Convenient(1) Insulin Pump Experience DUBLIN - February 21, 2018 -- (Healthcare Sales & Marketing Network) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, to... Devices, Drug Delivery, Product Launch Medtronic, MiniMed, Mio Advance, Infusion Set, insulin pump, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 21, 2018 Category: Pharmaceuticals Source Type: news

Aesculap, Inc. Acquires Dextera Surgical Inc.
CENTER VALLEY, Pa., Feb. 21, 2018 -- (Healthcare Sales & Marketing Network) -- Aesculap, Inc. is pleased to announce the asset acquisition of Dextera Surgical Inc. Aesculap is an industry expert in providing comprehensive solutions and differentiated tech... Devices, Surgery, Mergers & Acquisitions Aesculap, B. Braun, Dextera Surgical (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 21, 2018 Category: Pharmaceuticals Source Type: news

Dynatronics Corporation Announces Leadership Transition
COTTONWOOD HEIGHTS, Utah, Feb. 21, 2018 -- (Healthcare Sales & Marketing Network) -- Dynatronics Corporation (NASDAQ: DYNT) today announced leadership changes to its Board of Directors and executive management team, including the separation of its chairma... Devices, Personnel Dynatronics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 21, 2018 Category: Pharmaceuticals Source Type: news

Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR(R)
BRIDGEWATER, N.J., Feb. 21, 2018 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals has launched memantine hydrochloride extended-release capsules, the company's AB-rated equivalent for Namenda XR®, in 7 mg, 14 mg, 21 mg and 28 mg str... Biopharmaceuticals, Generics, Product Launch Amneal Pharmaceuticals, memantine, Namenda (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 21, 2018 Category: Pharmaceuticals Source Type: news

Pharmaceutical Startup, Bridge Therapeutics, Names David H. Bergstrom, Ph.D. as New Chief Operating Officer
BIRMINGHAM, Ala., Feb. 21, 2018 -- (Healthcare Sales & Marketing Network) -- The innovative late development-stage pharmaceutical startup, Bridge Therapeutics®, has named David H. Bergstrom, Ph.D. as its new Chief Operating Officer effective immediate... Biopharmaceuticals, Drug Delivery, Personnel Bridge Therapeutics, buprenorphine, meloxicam, sublingual (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 21, 2018 Category: Pharmaceuticals Source Type: news

Peritech Pharma's Novel Hemorrhoids Treatment Commercialized in 24 Countries
Deal includes local manufacturing and marketing in Central and South America, and the Caribbean HERZLIYA, Israel, Feb. 20, 2018 -- (Healthcare Sales & Marketing Network) -- Peritech Pharma, a specialty anal-rectal pharmaceutical company, today announce... Biopharmaceuticals, Licensing Peritech Pharma, hemorrhoids (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 20, 2018 Category: Pharmaceuticals Source Type: news

Johnson and Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics
PARIS, Feb. 20, 2018 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson Medical Devices Companies, through French affiliate Apsis S.A.S., announced today the acquisition of Orthotaxy, a privately-held developer of software-enabled surgery tech... Devices, Mergers & Acquisitions Johnson & Johnson, DePuy Synthes, Orthotaxy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 20, 2018 Category: Pharmaceuticals Source Type: news

Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
Members include world-renowned experts in biomarker-defined cancers, bioengineering, drug discovery and clinical development CAMBRIDGE, Mass., Feb. 20, 2018 -- (Healthcare Sales & Marketing Network) -- Merrimack Pharmaceuticals (Nasdaq: MACK), a clinic... Biopharmaceuticals, Oncology, Personnel Merrimack Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 20, 2018 Category: Pharmaceuticals Source Type: news

GenePOC Launches Its revogene(TM) Instrument and GBS LB Test in Canada
QUÉBEC CITY, February 19, 2018 -- (Healthcare Sales & Marketing Network) -- GenePOC Inc., member of the Debiopharm Group™, is proud to announce the launch in its home market for the revogene instrument and the GenePOC™ GBS LB assay. About Group ... Diagnostics, Product Launch GenePOC, Debiopharm, revogene, Group B Streptococcus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 19, 2018 Category: Pharmaceuticals Source Type: news

Blockchain Based Medical Device from NnBU Set to Raise €15million in ICO
New Neonatal Birth Unit is a World First to Improve Health Outcomes of Babies Born by C-Section NICOSIA, Cyprus, February 19, 2018 -- (Healthcare Sales & Marketing Network) --Today, Monday February 19 2018, NnBU Holdings Ltd (https://nnbu.io) announces... Devices, Venture Capital NnBU Holdings, blockchain, neonatal birth unit (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 19, 2018 Category: Pharmaceuticals Source Type: news

AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Reductions in the impact of genital psoriasis on sexual activity seen as early as one week INDIANAPOLIS, Feb. 19, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe ... Biopharmaceuticals, Dermatology Eli Lilly, Taltz, ixekizumab, genital psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 19, 2018 Category: Pharmaceuticals Source Type: news

Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors
CAMBRIDGE, Mass., Feb. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately... Biopharmaceuticals, Personnel Editas Medicine, genomic medicine, CRISPR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 16, 2018 Category: Pharmaceuticals Source Type: news

Photocure Announces U.S. FDA Approval of New Indication for Blue Light Cystoscopy with Cysview(R)
OSLO, Norway, Feb. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Photocure ASA (OSE: PHO), announced today that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) to extend the indication for Blue Lig... Devices, Oncology, FDA Photocure, KARL STORZ, Blue Light Cystoscopy, Cysview, bladder cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 16, 2018 Category: Pharmaceuticals Source Type: news

Arena Pharmaceuticals Announces Changes to Board of Directors
SAN DIEGO, Feb. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced Scott H. Bice, Phillip M. Schneider, and Christine A. White, M.D. have indicated that they will be retiring from the Board of... Biopharmaceuticals, Personnel Arena Pharmaceuticals, pulmonary arterial hypertension, Crohn's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 16, 2018 Category: Pharmaceuticals Source Type: news

Perflow Medical Closes $12 Million in Financing to Treat Complex Neurovascular Disorders
Announces successful completion of over 50 commercial cases with the Stream™ Dynamic Neuro-Thrombectomy Net TEL AVIV, Israel, Feb. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Perflow Medical, an Israeli-based medical device company that devel... Devices, Interventional, Neurology, Venture Capital Perflow Medical, CEREBRAL NET, Thrombectomy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 15, 2018 Category: Pharmaceuticals Source Type: news

Viz.ai Granted De Novo FDA Clearance for First Artificial Intelligence Triage Software
A new era of intelligent stroke care begins as regulatory approval is granted for the Viz.ai LVO Stroke Platform The platform utilizes artificial intelligence to identify Large Vessel Occlusion (LVO) strokes and automatically notify specialists to speed... Devices, Radiology, Neurology, FDA Viz.ai, imaging, artificial intelligence, stroke (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 15, 2018 Category: Pharmaceuticals Source Type: news

Arterys Receives First FDA Clearance for Broad Oncology Imaging Suite with Deep Learning
FDA clearance covers all solid tumors. Initial launch will include Liver AI and Lung AI oncology software to empower clinicians to quickly measure and track lesions and nodules in MRI and CT scans SAN FRANCISCO, Feb. 15, 2018 -- (Healthcare Sales & Mark... Devices, Radiology, Oncology, FDA Arterys, imaging, artificial intelligence (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 15, 2018 Category: Pharmaceuticals Source Type: news

GT Biopharma Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer
WASHINGTON, DC, February 15, 2018 -- (Healthcare Sales & Marketing Network) -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) ("GT" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercializat... Biopharmaceuticals, Oncology, Personnel GT Biopharma, lymphoma, leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 15, 2018 Category: Pharmaceuticals Source Type: news

Edwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark
IRVINE, Calif., Feb. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it has rece... Devices, Cardiology, Regulatory Edwards Lifesciences, CENTERA, self-expanding, TAVR, aortic valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 15, 2018 Category: Pharmaceuticals Source Type: news

Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
RG7716 is the first bispecific antibody designed specifically for the treatment of retinal eye diseases RG7716 demonstrated clinically meaningful and statistically significant improvements in visual acuity Key secondary and exploratory anatomical out... Biopharmaceuticals, Ophthalmology Genentech, Roche Group, diabetic macular edema, Anti-VEGF, Anti-Angiopoietin-2 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2018 Category: Pharmaceuticals Source Type: news

Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Lotion USP (Augmented), 0.05%
BUENA, N.J., Feb. 14, 2018 -- (Healthcare Sales & Marketing Network) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (A... Biopharmaceuticals, Generics, FDA Teligent, Betamethasone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2018 Category: Pharmaceuticals Source Type: news

Plastic And Reconstructive Surgery Journal Publishes Ten-Year Clinical Study Data Highlighting Safety Of MENTOR(R) MemoryShape(R) Gel Breast Implants
New publication adds to substantial clinical data demonstrating safety and effectiveness of MENTOR® Breast Implants in primary and revision augmentation and reconstruction patients IRVINE, Calif., Feb. 14, 2018 -- (Healthcare Sales & Marketing Netwo... Devices Mentor Worldwide, Johnson & Johnson , MENTOR , MemoryShape, breast implant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2018 Category: Pharmaceuticals Source Type: news

Cantel Medical Promotes Lawrence Conway to Senior Vice President, Business Systems and Integration
LITTLE FALLS, N.J., Feb. 14, 2018 -- (Healthcare Sales & Marketing Network) -- CANTEL MEDICAL CORP. (NYSE: CMD) announced today that Lawrence Conway has been recently appointed to Senior Vice President, Business Systems and Integration. In this role, Mr. ... Devices, Personnel Cantel Medical (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2018 Category: Pharmaceuticals Source Type: news

Galmed Announces ARRIVE Study Data
TEL AVIV, Israel, Feb. 14, 2018 -- (Healthcare Sales & Marketing Network) -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver tar... Biopharmaceuticals Galmed Pharmaceuticals, Aramchol, nonalcoholic steatohepatitis, NASH (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2018 Category: Pharmaceuticals Source Type: news

Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft(TM)C9T1 Skin Tissue
Study of Genetically Engineered Human Skin Substitute to Assess Safety and Tolerability in the Treatment of Diabetic Foot Ulcers STAINES-UPON-THAMES, United Kingdom, Feb. 14, 2018 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK... Devices, Wound Care Mallinckrodt plc, ExpressGraft-C9T1, diabetic foot ulcers (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2018 Category: Pharmaceuticals Source Type: news

SanBio and Teijin to Terminate Licensing Agreement regarding SB623 for Stroke Treatment
Tokyo, Japan, February 14, 2018 --(Healthcare Sales & Marketing Network)-- SanBio, Inc. and Teijin Limited jointly announced today that they would terminate the exclusive licensing agreement signed in 2009 regarding the development and marketing of SB623 f... Biopharmaceuticals, Neurology, Licensing Teijin Limited, SanBio Inc, stroke (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2018 Category: Pharmaceuticals Source Type: news

Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
DANVERS, Mass., Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has received an expanded U.S. Food and Drug Administ... Devices, Cardiology, FDA Abiomed, Impella, ventricular support, Cardiomyopathy, Cardiogenic Shock (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news

SANUWAVE Announces Strategic Partnership With Premier Shockwave
Dermapace Enters VA, Indian Health Services, and Military Base Market Revenues Expected to Occur Immediately SUWANEE, GA, Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce a partners... Devices, Wound Care SANUWAVE Health, Premier Shockwave, dermaPACE, diabetic foot ulcer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news

Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.
STAINES-UPON-THAMES, United Kingdom, Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Sucampo Pharmaceuticals, Inc.... Biopharmaceuticals, Mergers & Acquisitions Mallinckrodt, Sucampo Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news

Aptinyx Appoints Ashish Khanna Chief Financial Officer and Chief Business Officer
EVANSTON, Ill., Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Ashish Khanna, the company's chie... Biopharmaceuticals, Neurology, Personnel Aptinyx, neuropathic pain, PTSD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves New HPV Test that Detects and Identifies HPV Genotypes that put Women at High Risk for Cervical Cancer
The BD Onclarity™ HPV Assay can detect 14 high-risk HPV types and provide additional information to guide physician decision-making FRANKLIN LAKES, N.J., Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYS... Diagnostics, FDA BD , BD Onclarity, HPV assay, human papillomavirus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news

Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS, Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and e... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, Ankylosing Spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news

Sandoz announces US FDA approval and launch of Glatopa(R) 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched in the US in June 2015, will offer patients a compl... Biopharmaceuticals, Generics, FDA, Product Launch Sandoz, Novartis, Glatopa, glatiramer, Copaxone, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news

Ferring's CLENPIQ(TM) (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep Now Available
First and only FDA-Approved, Ready-to-Drink Low-Volume Bowel Prep PARSIPPANY, N.J., Feb. 12, 2018 -- (Healthcare Sales & Marketing Network) -- Ferring Pharmaceuticals Inc. announced today that CLENPIQ™ (sodium picosulfate, magnesium oxide, and anhydrou... Biopharmaceuticals, Gastroenterology, Product Launch Ferring Pharmaceuticals, CLENPIQ, Colonoscopy Prep, Colonoscopy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2018 Category: Pharmaceuticals Source Type: news

ImmunoMet Appoints Vincent J. O'Neill, M.D., B.Sc., M.R.C.P, as Chief Medical Officer, and Allan L. Shaw as Chief Financial Officer
HOUSTON, Feb. 12, 2018 -- (Healthcare Sales & Marketing Network) -- ImmunoMet Therapeutics, a private biotechnology company focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies, today announced the appointment... Biopharmaceuticals, Oncology, Personnel ImmunoMet Therapeutics, immunotherapy, immunotherapies (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2018 Category: Pharmaceuticals Source Type: news

Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial
TARRYTOWN, N.Y., Feb. 12, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced the appointment of Marion McCourt as the Senior Vice President and Head of Commercial. Ms. McCourt joined Regeneron... Biopharmaceuticals, Personnel Regeneron Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2018 Category: Pharmaceuticals Source Type: news

Ardelyx Announces Departure of Chief Scientific Officer
FREMONT, Calif., Feb. 12, 2018 -- (Healthcare Sales & Marketing Network) -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Jeremy Caldwell, Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018, to pursue a position ... Biopharmaceuticals, Personnel Ardelyx, tenapanor, hyperphosphatemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2018 Category: Pharmaceuticals Source Type: news